ArticleCureus2025
Longitudinal Study of IgG Antibody Levels Over 4.5 Years Until the Fifth Booster mRNA Vaccination and Breakthrough Infection: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The differential antibody responses and persistence of immunity following booster vaccinations and breakthrough infections with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) remain inadequately understood. This case study examined a 71-year-old Japanese man who received his seventh dose (fifth booster) of the mRNA BNT162b2 vaccine and subsequently experienced his first breakthrough infection 80 days after vaccination. A total of twenty-three serological assays were performed to quantify anti-spike protein immunoglobulin G (IgG) antibody levels from one week to one year and eight months post-infection. Six weeks after infection, the antibody titer peaked at 76,000 AU/ml, which was 14 times higher than the baseline level (5,555 AU/ml). At one year and eight months post-infection, the titer remained at 19,000 AU/ml, representing 3.8 times the baseline and one-fourth of the peak value observed after the sixth vaccination. The decline in antibody titers after breakthrough infection was modeled using the equation f(t) = Aexp(-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.